Clinical Use of New Insulins and New Insulin Delivery Systems.
10.4093/jkd.2015.16.4.242
- Author:
Tae Seok LIM
1
;
Seung Hyun KO
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. kosh@catholic.ac.kr
- Publication Type:Review
- Keywords:
Diabetes mellitus;
Insulin;
Insulin delivery system
- MeSH:
Diabetes Mellitus;
Glucose;
Half-Life;
Hypoglycemia;
Injections, Subcutaneous;
Insulin*;
Insulins*;
Weight Gain;
Insulin Glargine
- From:Journal of Korean Diabetes
2015;16(4):242-251
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Insulin plays an important role in the treatment of diabetes. Since it was discovered in the early 1920s, major advances have been made in the medical use of insulin. However, certain insulin associated challenges remain, such as hypoglycemia, weight gain, complex management, and injection site pain. Novel insulins and delivery systems are being developed that can address these limitations. Insulin degludec is a novel basal insulin with a long half-life (25 hours) and action duration (> 42 hours). Glargine U300 is a concentrated formulation of insulin glargine. For improvement in postprandial glucose control, ultrarapid-acting insulins are being investigated. New insulin delivery systems including inhaled insulin and insulin patches are also being developed to overcome the inconvenience associated with subcutaneous injection. In this review, clinical studies of new insulins and new insulin delivery systems are summarized.
